Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS
Phase 3
Completed
- Conditions
- PertussisTetanusPoliomyelitisDiphtheria
- Interventions
- Biological: DTaP-IPV combination vaccineBiological: DTaP vaccine and IPV vaccine
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 476
- Registration Number
- NCT02458183
- Locations
- ๐ฐ๐ท
Wonkwang University Hospital, Iksan, Korea, Republic of
๐ฐ๐ทInje University Busan Paik Hospital, Busan, Korea, Republic of
๐ฐ๐ทInha University Hospital, Incheon, Korea, Republic of
Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT02397538
- Locations
- ๐ฐ๐ท
Inje University Busan Paik Hospital, Busan, Korea, Republic of, Korea, Republic of
Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT02397590
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient(Kanarb-Hypertension Epidemiology Medication Satisfaction Study)
Completed
- Conditions
- Hypertension
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 12691
- Registration Number
- NCT02394392
- Locations
- ๐ฐ๐ท
Korea university Guro hospital, Seoul, Korea, Republic of
Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarbยฎ (Fimasartan)
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 601
- Registration Number
- NCT02385721
- Locations
- ๐ฐ๐ท
Yoon Jun Kim, Seoul, Korea, Republic of
A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide
Phase 2
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 103
- Registration Number
- NCT02222480
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 86
- Registration Number
- NCT02205151
- Locations
- ๐ฐ๐ท
The Catholic university St. Mary hospital, Seoul, Korea, Republic of
to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 81
- Registration Number
- NCT02205190
- Locations
- ๐ฐ๐ท
Kyungpook National University Hospital, Daegu, Korea, Republic of
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
Phase 3
Completed
- Conditions
- Essential Hypertension, Dyslipidemia
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT02166814
- Locations
- ๐ฐ๐ท
The Catholic university St. Mary hospital, Seoul, Korea, Republic of
๐ฐ๐ทSeoul university Bundang hospital, Bundang, Korea, Republic of
๐ฐ๐ทChungNam university hospital, ChungNam, Korea, Republic of
Fimasartan/Amlodipine Combination Phase III
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 143
- Registration Number
- NCT02152306
- Locations
- ๐ฐ๐ท
Seoul National University Bundang Hospital, Bundang, Gyeonggi, Korea, Republic of
ยฉ Copyright 2025. All Rights Reserved by MedPath